Dong-A Pharmaceutical and Newine Sign Exclusive Sales Agreement for Migraine Medical Device

Dong-A Pharmaceutical announced on the 14th that it signed an exclusive domestic sales supply contract for a migraine relief medical device with NewAin, a specialized electronic medicine research and development company, at Dong-A Pharmaceutical headquarters in Yongdu-dong, Dongdaemun-gu, Seoul on the 13th.

Baek Sang-hwan, CEO of Dong-A Pharmaceutical, Kim Do-hyung, CEO of Newine, and Choi Ho-jin, Vice Chairman of Dong-A Pharmaceutical (from left), are posing for a commemorative photo at the signing ceremony for the exclusive supply contract of the tonsillitis medical device.
[Photo by Dong-A Pharmaceutical]

Earlier, the two companies had signed a business agreement in November last year for mutual cooperation in clinical research and business development of chronic disease treatment technologies such as migraine, dry eye syndrome, and sleep improvement. With the signing of the migraine relief medical device supply contract this year, collaboration between the two companies is expected to become more active.

Under this contract, Dong-A Pharmaceutical will exclusively sell the migraine relief medical device in Korea, which is the only device in the country to have obtained premarket approval (510K) from the U.S. Food and Drug Administration (FDA) and certification under the European Medical Device Directive (CE-MDD). NewAin will be responsible for the production and product after-sales service (A/S) of this medical device.

The migraine relief medical device is a wearable device applied to the forehead, equipped with two functions: an acute mode that alleviates pain and a preventive mode that reduces the frequency of migraine attacks. It sends microcurrent stimulation to the trigeminal nerve located around the forehead, modulating the nerve to relieve migraines and reduce the frequency of their occurrence.

NewAin is a specialized electronic medicine medical technology research and development (R&D) company that develops electronic medicines applying drug-alternative therapies by artificially controlling nerve signals through electrical stimulation to treat or alleviate immune and metabolic-related diseases.

A Dong-A Pharmaceutical official said, “As a medical device that has passed stringent certifications in the U.S. and Europe, we believe it will be a good option as a digital healthcare solution for migraine patients,” adding, “We will continue to focus on strengthening new businesses and securing new growth engines to leap forward as a consumer-centered healthcare specialized company.”

This content was produced with the assistance of AI translation services.